《半新股》赤子城(09911.HK)跌至2.27元獲承接 反彈倒升16%
上市第四個交易天的赤子城科技(09911.HK)繼2019年除夕日(31日)首日掛牌最多飆升1.3倍至3.87元遇阻,掉頭反覆回落,今早曾反覆低見2.27元上市新低獲承接,掉頭節節向上,午後高見2.81元,現造2.77元,急彈16%,結束兩連跌,成交已達4,409萬股,涉資1.14億元。
赤子城是一家高速發展以AI技術為支撐的移動應用開發者及移動廣告平台服務提供商。公司上市以每股1.68元合共發售1.36億股,公開發售獲近1,441倍超購,認購一手中籤率僅2%。(sz/t)~
阿思達克財經新聞
網址: www.aastocks.com
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.